Skip to content
Buy This GLP
← Research
Evidence

Total spending: put the drug back in and it goes up

GLP-1 users spent $2,586 less per year on non-drug medical care and $2,019 less on acute care. Their total medical spending was still higher.

Neil Sanders6 min read
Same-year spending, per person-yearnon-drug medical−$2,586acute care−$2,019total spendinghigherThe other spending fell. The bill still went up.

There is a version of this finding that gets quoted as proof these drugs pay for themselves, and a version quoted as proof they do not, and this study contains both. It is also the missing half of the offset study that excluded the drug’s own cost.

What was measured

A cohort of 7,144 person-year records from a nationally representative US household survey between 2018 and 2022, with body-mass-index-defined analyses restricted to two of those years. [1] 275 of those person-years were sustained GLP-1 users.

That is a small exposed group, and it is a survey rather than an insurer’s claims file — households reporting their own spending and conditions, with the strengths and errors that implies, and a different set of them from a study built from insurer claims.

Both directions, in one result

Non-drug medical spending among users was lower by $2,586 per person-year. Acute-care spending was lower by $2,019. Those are real reductions in the part of the bill that is not the prescription.

Total medical spending was higher, with a coefficient of 0.3182. The published abstract truncates before the corresponding dollar figure, so this page does not carry one — a coefficient without its baseline cannot be turned into money honestly.

The year is the limit

Everything here is same-year. A person who starts a GLP-1 in March is being compared on that calendar year’s spending.

Cost-effectiveness models put the savings from these drugs years out, in cardiovascular events and complications that do not happen — which is exactly where a thirty-year model looks for them and where a single-year analysis cannot. “No same-year savings” is a statement about twelve months, not about the drug.

What a cash buyer takes from it

That the reductions are real and they land on somebody else’s ledger. Non-drug medical spending falling by $2,586 is money not spent by whoever was paying the hospital.

If you are buying from a telehealth seller with your own money, you are carrying the increase and an insurer is collecting the decrease — the same split as every offset finding on this site, and the reason what six months actually costs you is a different number from what a system saves.

Frequently asked

Do these drugs pay for themselves?
Not within the same year. Non-drug and acute-care spending both fell, and total medical spending was higher, which the authors describe as a shift in composition rather than a saving.
How much did other spending fall?
$2,586 per person-year for non-drug medical spending and $2,019 for acute care.
How much did total spending rise?
The direction is reported with a coefficient of 0.3182, and the published abstract truncates before the dollar figure, so it is not quoted here.
Could savings arrive later?
This design cannot see them. It compares spending within a single year, and cost-effectiveness models place the savings years further out.

Sources

  1. [1] Çelebi O, et al. (2026). GLP-1 Use, Downstream Medical Spending, and Acute-Care Burden Among Adults with BMI-Defined Obesity: An Overlap-Weighted MEPS Analysis Healthcare. PMID 42588330

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk

More in Evidence